The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
 
Andrew H. Ko
Consulting or Advisory Role - ARMO Biosciences; EMD Serono; Halozyme; Incyte; Merrimack
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); Celgene (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Merrimack (Inst); PharmaEngine (Inst); PRISM BioLab (Inst); Seagen (Inst)
 
Patrick B. Murphy
No Relationships to Disclose
 
James D. Peyton
No Relationships to Disclose
 
Dianna Shipley
No Relationships to Disclose
 
Ahmed Al-Hazzouri
No Relationships to Disclose
 
Frank A. Rodriguez
No Relationships to Disclose
 
Mark S. Womack
No Relationships to Disclose
 
Henry Q. Xiong
No Relationships to Disclose
 
David M. Waterhouse
No Relationships to Disclose
 
Margaret A. Tempero
Consulting or Advisory Role - AstraZeneca; Asuragen; Bayer; Celgene; Myriad Genetics; Nucana; Pfizer; Portola Pharmaceuticals; Roche/Genentech
 
Johanna C. Bendell
No Relationships to Disclose